Samsung Stops Trials Of Hodgkin's Disease Biosimilar Over Safety Issues
This article was originally published in PharmAsia News
Executive Summary
South Korea's Samsung Electronics halted clinical trials of its SAIT101 biosimilar drug for treating Hodgkin's disease.